Incyte (INCY) Expected to Announce Quarterly Earnings on Tuesday

Incyte (NASDAQ:INCY) will likely be issuing its quarterly earnings data before the market opens on Tuesday, February 11th. Analysts expect the company to announce earnings of $1.57 per share and revenue of $1.14 billion for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Incyte Trading Down 0.6 %

Shares of INCY opened at $73.74 on Tuesday. The stock has a market capitalization of $14.21 billion, a P/E ratio of 526.75, a PEG ratio of 0.54 and a beta of 0.71. The company has a quick ratio of 1.82, a current ratio of 1.87 and a debt-to-equity ratio of 0.01. The firm has a fifty day simple moving average of $71.83 and a two-hundred day simple moving average of $68.87. Incyte has a twelve month low of $50.35 and a twelve month high of $83.95.

Insider Transactions at Incyte

In other news, insider Thomas Tray sold 650 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $69.31, for a total transaction of $45,051.50. Following the sale, the insider now owns 23,312 shares in the company, valued at $1,615,754.72. This represents a 2.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Steven H. Stein sold 12,352 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $72.69, for a total transaction of $897,866.88. Following the completion of the transaction, the executive vice president now owns 66,967 shares of the company’s stock, valued at approximately $4,867,831.23. The trade was a 15.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 23,375 shares of company stock valued at $1,737,578. Insiders own 17.60% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on INCY shares. JPMorgan Chase & Co. raised their target price on Incyte from $65.00 to $71.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. JMP Securities restated a “market perform” rating on shares of Incyte in a report on Tuesday, January 14th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Incyte in a research note on Friday, January 10th. William Blair reissued an “outperform” rating on shares of Incyte in a research report on Friday, December 13th. Finally, Bank of America raised shares of Incyte from a “neutral” rating to a “buy” rating and raised their target price for the stock from $68.00 to $90.00 in a research report on Tuesday, October 29th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $75.71.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.